Phyllodes Tumor (Cystosarcoma Phylloides)

Subscribe to Selected New Research on Phyllodes Tumor

155 relevant articles (2 outcomes, 20 trials/studies) found for this Disease

Description: A type of connective tissue neoplasm arising from intralobular stroma of the BREAST. It is characterized by the rapid enlargement of an asymmetric firm mobile mass. Histologically, its leaf-like stromal clefts are lined by EPITHELIAL CELLS.

Also Known As:

Cystosarcoma Phylloides; Cystosarcoma Phyllodes; Malignant Cystosarcoma Phyllodes; Cystosarcoma Phyllodes, Malignant; Phyllodes Tumors; Tumor, Phyllodes; Tumors, Phyllodes

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Histologic Type: 1

Connective and Soft Tissue Neoplasms

Sarcoma: 10707

Phyllodes Tumor: 155

Neoplasms by Site: 1

Breast Neoplasms: 65247

Phyllodes Tumor: 155

Skin and Connective Tissue Diseases

Skin Diseases: 6187

Breast Diseases: 954

Breast Neoplasms: 65247

Phyllodes Tumor: 155

Related Diseases

1.	Fibroadenoma
2.	Neoplasms (Cancer)
3.	Carcinoma (Carcinomatosis)
4.	Sarcoma (Soft Tissue Sarcoma)
5.	Neoplasm Metastasis (Metastasis)

Experts

1.	Law, Bonita K B: 2 articles (09/2004 - 11/2003)
2.	Tse, Gary M K: 2 articles (09/2004 - 11/2003)
3.	Singh, Gurpreet: 1 article (06/2008)
4.	Sharma, Ramesh K: 1 article (06/2008)
5.	Hortobagyi, Gabriel N: 1 article (11/2007)
6.	Broglio, Kristine: 1 article (11/2007)
7.	De La Garza, Jaime G: 1 article (11/2007)
8.	Gonzalez-Angulo, Ana Maria: 1 article (11/2007)
9.	Lopez-Basave, Horacio N: 1 article (11/2007)
10.	Gallardo, Dolores: 1 article (11/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Phyllodes Tumor:

1.	DNA (Deoxyribonucleic Acid)IBA 01/01/2001 - "Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases." 04/01/1990 - "The authors conclude that the DNA ploidy study is a useful, objective adjunct to the clinicopathologic assessment of cystosarcoma phyllodes of the breast." 11/01/2001 - "S-phase fraction and DNA ploidy analysis showed useful trends for improving outcome predictions in malignant phyllodes tumors. " 11/01/2001 - "Phyllodes tumors of the breast: correlation of nucleolar organizer regions with histopathological malignancy grading, flow cytometric DNA analysis and clinical outcome." 09/01/1993 - "When DNA samples were prepared from widely separated sites of phyllodes tumors, every sample was found to contain a monoclonal stromal cell component. " Order ALL the reference details at left...
2.	ParaffinIBA 01/01/1994 - "This study documents the reactions of the monoclonal antibody KP-1, which detects histiocytes in paraffin sections, with 137 sarcomas, 48 lymphomas, 28 carcinomas, 7 malignant melanomas and 8 cystosarcoma phyllodes. " 09/01/1999 - "We examined by immunohistochemistry in paraffin sections, the expression of E (epithelial), N- (neural), and P- (placental) cadherin in 36 unusual tumors of the breast (22 medullary carcinomas, 5 metaplastic carcinomas, 2 carcinosarcomas, 4 phyllodes tumors, and 3 periductal stromal tumors). " 10/01/2004 - "Laser-assisted microdissection was performed to extract epithelial and stromal components of phyllodes tumor from formalin-fixed, paraffin-embedded tissue. " 01/01/1985 - "The distribution pattern of fibronectin in metaplastic carcinomas, stromal sarcomas, malignant cystosarcoma phyllodes tumours and histiocytic type lymphomas of the human female breast has been studied using the indirect immunoperoxidase technique on formalin fixed paraffin embedded tissue. " 07/01/2006 - "METHODS AND STUDY DESIGN: An immunohistochemical panel with 37 primary antibodies including cytokeratins, mesenchymal markers, key regulators of the cell cycle, oncogenes, apoptosis-related proteins, metalloproteinases and their inhibitors was performed on a formalin-fixed paraffin-embedded sample of phyllodes tumor with osteosarcomatous differentiation in a 49-year-old woman. " Order ALL the reference details at left...
3.	AntibodiesIBA 01/01/1987 - "Six cases of invasive duct carcinoma (IDC) and two cases of cystosarcoma phyllodes (CP) were compared to SCB using the same panel of antibodies. " 12/01/1991 - "Argyrophil cells found in the phyllodes tumor gave positive reaction to both anti-EGC and anti-serotonin antibodies. " 01/01/2001 - "Proliferating activity, determined by immunohistochemistry with PCNA and Ki-67 antibodies did not reveal significant difference between phyllodes tumor and fibroadenoma." 01/01/1981 - "Antibodies to prekeratin which characterize cells of epithelial origin, and antibodies to vimentin which recognize cells of mesenchymal origin have been used to study twenty cases of breast carcinoma (sixteen infiltrating ductal carcinomas and four infiltrating intraductal carcinomas), two cases of cystic breast disease, two fibroadenomas and one case of benign cystosarcoma phylloides. " 07/01/2006 - "METHODS AND STUDY DESIGN: An immunohistochemical panel with 37 primary antibodies including cytokeratins, mesenchymal markers, key regulators of the cell cycle, oncogenes, apoptosis-related proteins, metalloproteinases and their inhibitors was performed on a formalin-fixed paraffin-embedded sample of phyllodes tumor with osteosarcomatous differentiation in a 49-year-old woman. " Order ALL the reference details at left...
4.	Estrogens (Estrogen)FDA Link 01/15/1985 - "A malignant cystosarcoma phyllodes with positive estrogen receptor and its heterotransplantation into nude mice." 04/01/2006 - "Conversely, the older age of patients with ER-beta-rich phyllodes tumors suggests that mechanisms, probably independent from estrogen stimulation, act on the growth of these tumors." 09/01/1989 - "The tumor was diagnosed as being a benign prostatic phyllodes tumor showing fibroblastic differentiation, and of an estrogen-dependent nature." 04/01/2006 - "In this study, the expression of estrogen receptor (ER)-alpha and -beta was investigated by immunohistochemistry in 33 fibroadenomas and in 30 benign, three borderline and seven malignant phyllodes tumors, all with spindle cell growth and in one distant metastasis. " 04/15/1981 - "Most cystosarcoma phyllodes and fibroadenomas have progesterone receptor but lack estrogen receptor: stromal localization of progesterone receptor." Order ALL the reference details at left...
5.	VimentinIBA 03/01/2005 - "The stromal component of all phyllodes tumors was positive for vimentin, whereas all other investigated markers were absent except for focal p63 and CD10 expression in 1 case each. " 11/01/1989 - "In the 4 benign cases of cystosarcoma phylloides, the stromal cells stained positively only for vimentin. " 04/01/2006 - "CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system." 05/01/1987 - "Vimentin and desmin were detected in the sarcomatous portion of carcinosarcoma, focally in the stromal component of phyllodes tumors and not always in the stromal sarcomas. " 01/01/1981 - "In cystic breast disease, fibroadenomas, and benign cystosarcoma phylloides, cells of epithelial origin were strongly stained by the prekeratin but not by the vimentin antibody." Order ALL the reference details at left...
6.	Progesterone Receptors (Progesterone Receptor)IBA 05/01/1977 - "Progesterone receptor in cystosarcoma phyllodes." 04/15/1981 - "Biochemical study of fibroepithelial tumors of the female breast showed presence of progesterone receptor (PgR) in all five cystosarcoma phyllodes (two malignant, three benign), and in 11 of 13 fibroadenomas tested. " 04/15/1981 - "Most cystosarcoma phyllodes and fibroadenomas have progesterone receptor but lack estrogen receptor: stromal localization of progesterone receptor." 10/01/2002 - "We used immunohistochemical analysis to detect the presence of estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR) protein expression in the epithelial and stromal cells of 143 phyllodes tumors (PTs). " 03/01/1986 - "Tissue carcinoembryonic antigen (CEA) and cytosolic estrogen and progesterone receptors were studied in 15 patients with cystosarcoma phyllodes (CSP) aiming at predicting recurrence of the tumor. " Order ALL the reference details at left...
7.	Proteins (Proteins, Gene)IBA 01/01/1979 - "One of the five cystosarcoma phylloides and five of the six nonmammary sarcoma tissues contained ER (mainly of the 4 Svedburg (S) variety) of more than 7 femtomoles (fmoles)/mg cytosol proteins (6/11 = 54%). " 05/01/2005 - "We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 21; borderline, 8; malignant, 11) and 7 recurrent tumors of different grades. " 07/01/2006 - "METHODS AND STUDY DESIGN: An immunohistochemical panel with 37 primary antibodies including cytokeratins, mesenchymal markers, key regulators of the cell cycle, oncogenes, apoptosis-related proteins, metalloproteinases and their inhibitors was performed on a formalin-fixed paraffin-embedded sample of phyllodes tumor with osteosarcomatous differentiation in a 49-year-old woman. " 05/01/1987 - "The distribution of intermediate-filament (IF) proteins of the keratin, vimentin and desmin type in breast stromal sarcomas, carcinosarcomas, metaplastic carcinomas and phyllodes tumors has been compared using the avidin-biotin complex immunoperoxidase technique. " Order ALL the reference details at left...
8.	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 12/01/2005 - "In this study, we determined if p53 and CD117 (c-kit) protein expression was predictive of behavior in a series of 335 phyllodes tumors diagnosed at the Singapore General Hospital, using immunohistochemistry on tissue microarrays. " 05/01/2002 - "METHODS: The localization of c-kit protein was examined immunohistochemically in human breast, consisting of 366 normal tissue, 156 benign lesions (fibroadenoma, fibrocystic change, intraductal papilloma, benign phyllodes tumor, and gynecomastia), 13 borderline diseases (atypical ductal hyperplasia, atypical lobular hyperplasia, and borderline malignant phyllodes tumor), and 197 malignant lesions (non-invasive and/or invasive ductal carcinoma and malignant phyllodes tumor). " 07/01/2004 - "This provides strong evidence that c-kit receptor mediated tyrosine kinase involvement in the pathogenesis of phyllodes tumors, and the therapeutic agent, STI571, Glivec, may be a potentially useful drug for its management." Order ALL the reference details at left...
9.	Epidermal Growth Factor Receptor (EGF Receptor)IBA 04/01/2009 - "Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors." 01/01/2006 - "An important role of the epidermal growth factor receptor (EGFR) in phyllodes tumors has been proposed. " 01/01/2006 - "Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression." 02/01/2007 - "This study was undertaken to investigate both amplification of the epidermal growth factor receptor (EGFR) gene by fluorescence in situ hybridization and the overexpression of EGFR, Her-2/neu, CD117 (c-kit), and androgen receptor by immunohistochemical staining in a series of 11 phyllodes tumors of the prostate. " Order ALL the reference details at left...
10.	Androgen Receptors (Androgen Receptor)IBA 02/01/2007 - "Our data indicate that EGFR and androgen receptor are frequently and strongly expressed in both epithelial and stromal components of prostatic phyllodes tumors. " 02/01/2007 - "Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate." 02/01/1997 - "Androgen-receptor polymorphism also revealed a monoallelic X chromosome pattern in the recurrent phyllodes tumor tissue taken at autopsy, in addition to loss of heterozygosity demonstrated at locus TP53. " 02/01/2007 - "This study was undertaken to investigate both amplification of the epidermal growth factor receptor (EGFR) gene by fluorescence in situ hybridization and the overexpression of EGFR, Her-2/neu, CD117 (c-kit), and androgen receptor by immunohistochemical staining in a series of 11 phyllodes tumors of the prostate. " 10/01/2002 - "We used immunohistochemical analysis to detect the presence of estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR) protein expression in the epithelial and stromal cells of 143 phyllodes tumors (PTs). " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 09/01/2002 - "Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung." 02/01/2009 - "Temporary remission of a multirecurrent cystosarcoma phyllodes of the breast by using continuous chemotherapy." 11/01/1986 - "A review of the treatment recommendations for cystosarcoma phyllodes revealed that the surgical procedure of choice for the malignant variant has remained controversial, and the conclusions regarding the ineffectiveness of radiation and chemotherapy have been based on insufficient data handed down through the years. " 06/01/1985 - "Successful chemotherapy for cystosarcoma phyllodes in a young woman." 05/01/1982 - "In 1976, a 61-year-old female was diagnosed as malignant cystosarcoma phyllodes, and she was admitted to the hospital for chemotherapy. " Order ALL the reference details at left...
2.	Segmental Mastectomy (Lumpectomy) 10/01/1999 - "STUDY DESIGN: Since few patients with malignant phyllodes tumors have been treated with breast conserving surgery in any individual series, the literature was reviewed using a Medline search. " 08/01/2006 - "CONCLUSIONS: Breast-conserving surgery with clear margins is the current treatment of choice for phyllodes tumors, but this strategy does not further reduce local recurrence effectively. " 10/01/2000 - "CONCLUSIONS: Local failure in this group of largely margin negative patients with cystosarcoma phyllodes of the breast was low, showing that breast-conserving surgery with appropriate margins is the preferred primary therapy. " 10/01/1999 - "CONCLUSIONS: Malignant phyllodes tumors are much more likely than benign phyllodes tumors to recur in the breast after breast conserving surgery. " 08/01/2000 - "Cystosarcoma phyllodes: mastectomy, lumpectomy, or lumpectomy plus irradiation." Order ALL the reference details at left...
3.	Adjuvant Radiotherapy 08/01/2009 - "A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors." 08/01/2009 - "CONCLUSIONS: Margin-negative resection combined with adjuvant radiotherapy is very effective therapy for local control of borderline and malignant phyllodes tumors. " 08/01/2009 - "METHODS: We prospectively enrolled patients who were treated with a margin-negative breast-conserving resection of borderline malignant or malignant phyllodes tumors to adjuvant radiotherapy. " 03/01/2004 - "BACKGROUND AND PURPOSE: To evaluate the role of adjuvant radiotherapy for an unexpected malignancy of the breast, known as phyllodes tumor, a retrospective study was undertaken. " 01/01/1998 - "This retrospective review suggests that adjuvant radiotherapy may be underutilized in the treatment of phyllodes tumor of the breast, particularly in patients with adverse features. " Order ALL the reference details at left...
4.	Adjuvant Chemotherapy 11/01/2007 - "The purpose of this study was to evaluate the role of adjuvant chemotherapy in malignant phyllodes tumors of the breast treated at the Instituto Nacional de Cancerología of Mexico. " 08/01/2001 - "More research is required to determine the role of adjuvant chemotherapy and radiotherapy in the management of malignant cystosarcoma phyllodes [corrected]." 11/01/2007 - "Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast." 11/01/2007 - "Twenty-eight patients with malignant phyllodes tumors of the breast enrolled in a observational study from January 1993 to December 2003 to receive four cycles of adjuvant chemotherapy with doxorubicin 65 mg/m(2) over 48 hours intravenous infusion and dacarbazine 960 mg/m(2) over 48 hours intravenous infusion (n = 17) versus observation (n = 11). " Order ALL the reference details at left...
5.	Investigational Therapies (Experimental Therapy) 11/15/1988 - "This unique cell line, RW-972, presumably derived from the stromal component of a human malignant cystosarcoma phyllodes, might be useful in studies of experimental therapy of this rare tumor type and of lobular stromal cells of breast. " Order ALL the reference details at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>